VivoSeq
Cardiovascular

Ischemia

123

Pipeline Programs↗

18

Active Trials↗

46

Companies Involved↗

Ischemia is a highly competitive landscape with 123 programs across 46 companies. The most active players are Libella Gene Therapeutics, Acrotech Biopharma Inc., BioGenCell Ltd.. 27 therapies are approved with 19 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

73/100

Pipeline Velocity

25/100

Mech. Concentration

7/100

Completion Rate

80/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

L

Libella Gene Therapeutics

1 program

Phase 1A

Acrotech Biopharma Inc.

1 program

Phase 1B

BioGenCell Ltd.

2 programs

Phase 2M

Mast Therapeutics, Inc.

1 program

Phase 2L

Lisata Therapeutics, Inc.

1 program

Phase 2Q

Quince Therapeutics S.p.A.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical24

Ambrisentan

Gilead

Platelet Rich Plasma

Zagazig University

Iloprost

BTG International Inc.

Naloxone

Scienture

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 114

Enalapril

Bausch Health Americas, Inc.

BM-Ecs

South China Research Center for Stem Cell and Regenerative Medicine

Lactate

Rutgers, The State University of New Jersey

PLX-PAD

United Therapeutics

VM202

Helixmith Co., Ltd.

Phase 239

Clopidogrel

Sanofi

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Infliximab

Organon and Co

Epoetin Beta

Roche

Rivaroxaban

Wim Janssens

Phase 319

Adenosine

Astellas

Mannitol

B. Braun Medical Inc.

Diltiazem

Bausch Health Americas, Inc.

Metronidazole

DePuy Orthopaedics

Gentamicin

Schering-Plough

Approved27

Propofol

Fresenius Kabi Oncology Ltd.

Paclitaxel

Teva

Treprostinil

United Therapeutics

Enoxaparin

Sanofi

Cangrelor

Chiesi Farmaceutici S.p.A.

Analysis

Modality Breakdown

88%

Small molecule

115 of 131 classified programs — the dominant modality here.

12%ALL OTHERSCell therapy108%Monoclonal antibody22%Protein / enzyme1<1%Gene therapy1<1%Vaccine1<1%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 131 classified programs, each share of the total. Modality classified for 100% of 160 pipeline programs.

Analysis

Trial Status

139

clinical trials

Completed74 · 53%
Unknown status26 · 19%
Terminated12 · 9%
Recruiting7 · 5%
Not yet recruiting6 · 4%
Withdrawn4 · 3%
Other10 · 7%

Clinical Trials

Trial Activity

139 trials

ORal Antibiotics in Acute Mesenteric Ischemia
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06387147·196 enrolled
Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial
Recruiting·SSupergene, LLC·Phase 3·NCT05372718·170 enrolled
TP03HN106 in Patients With Critical Limb Ischemia
Recruiting·TTalengen Institute of Life Sciences, Shenzhen, P.R. China.·Phase 2·NCT06482892·15 enrolled
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
Recruiting·CCell Biopeutics Resources Sdn Bhd·Phase 4·NCT05854615·3 enrolled
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia
Recruiting·AAllife Medical Science and Technology Co., Ltd.·Phase 1·NCT06359912·27 enrolled
Early Vessel Recoil Following Below-the-knee (BTK) Artery Treatment With the Spur Peripheral Retrievable Scaffold System in Specific Patient Populations With Chronic Limb-threatening Ischemia (CLTI) - The DEEPER CHALLENGE Single Center Prospective Study
Recruiting·MMedical University of Graz·N/A·NCT07465627·40 enrolled
Prospective Multi-Center Randomized Controlled Trial to Evaluate the Safety and Efficacy of AcoArt Litos Paclitaxel Coated Percutaneous Transluminal Angioplasty (PTA) Balloon Versus Non-Coated Standard Balloon Angioplasty for the Treatment of Infrapopliteal Obstructions in Patients With Chronic Limb-Threatening Ischemia
Recruiting·AAcotec Scientific Co., Ltd·Preclinical·NCT06330493·288 enrolled
ISCHEMIA-EXTEND (Extended Follow-up)
Active, not recruiting·NNYU Langone Health·N/A·NCT04894877·5,391 enrolled
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Active, not recruiting·UUniversity of Florida·Phase 4·NCT03417388·2,476 enrolled
Safety Study of MultiGeneAngio in Patients With Chronic Critical Limb Ischemia
Active, not recruiting·MMultiGene Vascular Systems Ltd.·Phase 1/2·NCT00956332·28 enrolled
BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)
Active, not recruiting·BBioGenCell Ltd.·Phase 1/2·NCT02805023·40 enrolled
Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion
Not yet recruiting·MMilton S. Hershey Medical Center·Phase 1·NCT06369350·30 enrolled
Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury
Not yet recruiting·—·Phase 1·NCT06825143·68 enrolled
Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia
Not yet recruiting·UUPECLIN HC FM Botucatu Unesp·Phase 1/2·NCT06326203·40 enrolled
Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma/Stem Cells (AdMSC) Transplantation in Patients With Critical Limb Ischemia.
Not yet recruiting·UUniversity Hospital, Toulouse·Phase 1·NCT06795620·10 enrolled
Page 1 of 10

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)